Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) EBT Margin (2016 - 2025)

Historic EBT Margin for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 12.54%.

  • Protalix BioTherapeutics' EBT Margin fell 88600.0% to 12.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.49%, marking a year-over-year increase of 314800.0%. This contributed to the annual value of 7.78% for FY2024, which is 53000.0% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported EBT Margin of 12.54% as of Q3 2025, which was down 88600.0% from 4.22% recorded in Q2 2025.
  • Protalix BioTherapeutics' EBT Margin's 5-year high stood at 56.01% during Q2 2023, with a 5-year trough of 176.89% in Q2 2021.
  • Its 5-year average for EBT Margin is 33.34%, with a median of 30.62% in 2023.
  • As far as peak fluctuations go, Protalix BioTherapeutics' EBT Margin plummeted by -1387100bps in 2021, and later soared by 1169500bps in 2023.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' EBT Margin stood at 77.37% in 2021, then skyrocketed by 52bps to 37.25% in 2022, then crashed by -65bps to 61.28% in 2023, then surged by 166bps to 40.16% in 2024, then tumbled by -69bps to 12.54% in 2025.
  • Its last three reported values are 12.54% in Q3 2025, 4.22% for Q2 2025, and 36.9% during Q1 2025.